ALTME — TME Pharma NV Cashflow Statement
0.000.00%
Last trade - 00:00- €1.45m
- -€1.80m
Annual cashflow statement for TME Pharma NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.4 | -14.5 | -15.1 | -6.73 | -5.72 |
| Depreciation | |||||
| Non-Cash Items | 4.76 | 1.6 | 3.61 | 1.52 | 0.793 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.363 | 0.407 | -0.72 | -0.561 | 0.217 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -5.22 | -12.4 | -12.1 | -5.63 | -4.63 |
| Capital Expenditures | -0.039 | -0.014 | -0.021 | -0.019 | -0.016 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0 | — | — | -0.005 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.039 | -0.014 | -0.021 | -0.019 | -0.021 |
| Financing Cash Flow Items | -0.299 | -0.066 | -0.145 | 0.14 | 0.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.2 | 11.5 | 7.29 | 3.27 | 5.66 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.92 | -0.848 | -4.82 | -2.39 | 0.995 |